Literature DB >> 30066004

HER2 and Src co-regulate proliferation, migration and transformation by downstream signaling pathways in arsenite-treated human uroepithelial cells.

Qing Zhou1, Peiyu Jin, Jieyu Liu, Fei Wang, Shuhua Xi.   

Abstract

Epidemiological studies have established a strong association between arsenic exposure in drinking water and an increased incidence of bladder cancer in arseniasis-endemic areas. Increased expression of HER2 has been observed in various types of human malignancies including bladder cancer. This study investigated the role of HER2 in arsenite-induced transformation of uroepithelial cells SV-HUC-1 and the role of Src family kinases in HER2 signaling. We found that the expression HER2 and Src were increased following chronic arsenite exposure in a time-dependent fashion. Chronic arsenite exposure also led to an upregulation of proliferation factors such as cyclin D1, COX2, PCNA, VEGF, and HIF-1α. Furthermore, Ras/Raf/MAPK, PI3K/AKT, and JAK2/STAT3 signaling pathways were activated by arsenite treatment. Importantly, these changes were inhibited by HER2 inhibitors and in HER2 knocked down cells. In addition, downregulation of HER2 inhibited cell growth and migration properties of arsenite-treated cells. Inhibition of Src also inhibits activation of signaling pathways and malignant transformation of cells. And we obtained evidence of an interaction between HER2 and Src in SV-HUC-1 cell lines. These results suggest that HER2 and Src may play an important role in arsenite-induced transformation by multiple downstream signals pathways.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30066004     DOI: 10.1039/c8mt00131f

Source DB:  PubMed          Journal:  Metallomics        ISSN: 1756-5901            Impact factor:   4.526


  4 in total

1.  Long-term treatment with arsenite activates HER1 and HER2 through upregulating EGF, TGFα, and HSP90 in a human uroepithelial cell line.

Authors:  Peiyu Jin; Jieyu Liu; Qing Zhou; Sihao Li; Weijue Liu; Shuhua Xi
Journal:  Cell Biol Toxicol       Date:  2019-11-26       Impact factor: 6.691

2.  Homogeneous polyporus polysaccharide inhibits bladder cancer by polarizing macrophages to M1 subtype in tumor microenvironment.

Authors:  Wenyu Jia; Siwan Luo; Gena Lai; Shiqi Li; Shuai Huo; Meifang Li; Xing Zeng
Journal:  BMC Complement Med Ther       Date:  2021-05-25

3.  YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development.

Authors:  Miwa Fujihara; Tadahiko Shien; Kazuhiko Shien; Ken Suzawa; Tatsuaki Takeda; Yidan Zhu; Tomoka Mamori; Yusuke Otani; Ryo Yoshioka; Maya Uno; Yoko Suzuki; Yuko Abe; Minami Hatono; Takahiro Tsukioki; Yuko Takahashi; Mariko Kochi; Takayuki Iwamoto; Naruto Taira; Hiroyoshi Doihara; Shinichi Toyooka
Journal:  Int J Mol Sci       Date:  2021-11-26       Impact factor: 5.923

4.  Effect of hnRNPA2/B1 on the proliferation and apoptosis of glioma U251 cells via the regulation of AKT and STAT3 pathways.

Authors:  Decheng Yin; Chengxiang Kong; Muhu Chen
Journal:  Biosci Rep       Date:  2020-07-31       Impact factor: 3.840

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.